The Bengal Bite 🐯 | August Digest 2020
This Month's Newsletters and Most Read Articles:
From the Halls of Congress | August 7 MarketWatch | FDA releases guidelines for cannabis-related research, but CBD will have to wait: The US Food and Drug Administration released preliminary guidance on cannabis-related clinical research, outlining how companies seeking approval of drugs that contain cannabis or its derivatives must follow the traditional drug review and approval process involving clinical trials. The agency is still working on rules for products that contain the cannabis ingredient CBD; the 2018 Farm Bill legalized hemp but not CBD, and the FDA continues to do its due diligence on CBD while the public awaits guidelines on that compound.
The Momentum of Cannabis | August 14 New Cannabis Ventures | American cannabis operator stocks soar 27% in July: The American Cannabis Operator Index tracks the stocks of some of the largest operators in the American cannabis space. After posting an all-time closing low on March 18th (14.50), the index has recovered and is up more than 150% through mid August (37.97 as of August 12th).
The Rising Tide of Legalization | August 21 Investopedia | Barbarians at the gate: institutions are buying US cannabis stocks: “Big institutional investors are buying big slugs [of cannabis stocks], quietly.” Putnam and Fidelity, massive institutional asset managers, have holdings in some of the industry’s most recognized names including 4Front, Cresco Labs, Green Thumb Industries, and Curaleaf.
Cannabis Disruption | August 28 Forbes | Poll: Republicans like marijuana legalization, too (even if it's Kamala Harris's idea): Americans’ views on cannabis continue to normalize, fueling bipartisan support for cannabis legalization. A new poll conducted by progressive data firm Data For Progress suggests marijuana legalization is a winning issue among Republicans.